Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This study found that 1 mg/day low-dose oral minoxidil significantly increased hair count compared to 0.25 mg/day over 24 weeks in women with female pattern hair loss, though no differences were observed in hair-shedding and quality-of-life scores between the two doses.

This article reviews multiple entries on the Androlog blog regarding finasteride use, concluding that a 1-mg dose does not adversely affect spermatogenesis or pose a risk during conception or pregnancy.

This case report describes a 23-year-old man experiencing painful gynecomastia aggravated by low dose finasteride for androgenetic alopecia, which reversed after stopping the medication.

This case series reports the experience of using oral minoxidil at 1.25 mg/day in 32 patients with male androgenetic alopecia, noting both therapeutic effects and potential adverse reactions.

Finasteride lowers PSA levels about the same whether taken at 1 mg or 5 mg daily.

This case report observed that a 23-year-old man developed painful unilateral gynecomastia after two months of low-dose finasteride treatment for male androgenetic alopecia, which resolved after discontinuation.

This study observed that low-dose oral minoxidil and topical minoxidil 5% solution both improved hair density in women with female-pattern hair loss, but oral minoxidil may offer advantages in reducing hair shedding.

Higher doses of oral minoxidil can help hair growth but need careful monitoring for side effects.

In this study, dose-response modeling predicted that once-daily abrocitinib doses of 100 mg and 200 mg may provide a clinically meaningful response in treating moderate-to-severe atopic dermatitis compared to placebo.

This study found that a daily dose of 1 mg finasteride is effective for treating male pattern baldness, but benefits typically require at least three months to manifest and ongoing treatment is necessary to maintain results.

In this study, 1 mg/day finasteride lowered serum PSA concentration in men aged 40–60, suggesting that PSA adjustment recommendations for prostate cancer screening using 5 mg/day finasteride should also apply to this lower dose for hair loss treatment.

This study found that oral minoxidil increased the growth rates of nails and hair in healthy adult men, with 2.5mg proving more effective for nails than 1mg, and both doses boosting hair growth, without significant adverse effects.

This pilot study found that among male androgenetic alopecia patients, 2.5 mg oral minoxidil with platelet-rich plasma led to higher patient satisfaction than 1.25 mg, though hair count improvements were not statistically significant.

This article concludes that finasteride is a safe treatment for androgenetic alopecia and does not increase the risk of high-grade prostate cancer, despite past concerns from the Prostate Cancer Prevention Trial.

This study concluded that finasteride 1 mg does not significantly affect the metabolism of omeprazole in young healthy Japanese male extensive or poor metabolizers for CYP2C19.

In this study, oral minoxidil treatment at 2.5 mg/day significantly increased nail growth speed by 50.7% and hair growth speed by 35.9% in healthy adult men, while also increasing heart rate but not affecting blood pressure.

In this study, 1.25 mg daily finasteride for 28 weeks showed minimal increase in hair density and thickness in normoandrogenic female pattern hair loss, but no significant clinical improvement was observed.

This study suggests that while hair analysis using GC-MS is a sensitive method for detecting cocaine ingestion, it may not reliably indicate the amount, timing, or duration of drug use due to interindividual variability and multiple incorporation mechanisms.

Taking 1mg of finasteride daily for hair loss can lower PSA levels by 40-50%, so to keep PSA effective as a cancer screening tool, the PSA value should be doubled during treatment.

In this study, oral minoxidil (1.25 mg and 2.5 mg) and topical 5% minoxidil significantly promoted hair regrowth in men with androgenetic alopecia over six months, showing comparable efficacy across both oral and topical treatments.

This meta-analysis found that deuruxolitinib significantly improved hair regrowth and patient satisfaction in those with moderate to severe alopecia areata compared to placebo, though it was associated with manageable side effects such as elevated creatinine kinase levels, headaches, and acne, especially at higher doses.

In this study, men taking 1 mg/day of finasteride for 12 months showed minor metabolic changes and slight improvements in glucose metabolism.

This study found that deuruxolitinib may effectively improve hair regrowth and patient satisfaction in moderate to severe alopecia areata, but careful monitoring is needed due to manageable side effects and concerns about long-term safety.

This systematic review and meta-analysis reported that deuruxolitinib is effective for hair regrowth and improving patient-reported outcomes in individuals with moderate to severe alopecia areata, but observed manageable treatment-emergent adverse events such as elevated creatinine kinase levels and headaches, particularly with higher doses.

ASLAN004 was safe and well-tolerated, supporting further development for treating certain diseases.

This study found that a single dose of 1 mg/kg dexamethasone promoted wound healing in septic mice but delayed it in normal mice.

This study concluded that while both 5% topical and 1 mg oral minoxidil significantly improved hair diameter in androgenetic alopecia patients, there was no significant difference in overall effectiveness or patient satisfaction between the treatments.